Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 374

1.

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?

Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Aug;30(8):1521-8. doi: 10.1185/03007995.2014.916159. Epub 2014 May 2.

PMID:
24758611
2.

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Apr;30(4):645-53. doi: 10.1185/03007995.2013.867843. Epub 2013 Dec 5.

PMID:
24256067
3.

Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.

Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Hosp Pract (1995). 2014 Aug;42(3):17-25. doi: 10.3810/hp.2014.08.1114.

PMID:
25255403
4.

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Mar;32(3):216-27. doi: 10.1007/s12325-015-0189-1. Epub 2015 Mar 18. Erratum in: Adv Ther. 2015 Apr;32(4):387.

5.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Jul;30(7):1317-25. doi: 10.1185/03007995.2014.907140. Epub 2014 Apr 2.

PMID:
24650301
6.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Clin Ther. 2015 Mar 1;37(3):554-62. doi: 10.1016/j.clinthera.2015.02.001. Epub 2015 Mar 4. Erratum in: Clin Ther. 2015 Aug;37(8):1870-1.

7.

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

J Med Econ. 2013 Sep;16(9):1163-8. doi: 10.3111/13696998.2013.826664. Epub 2013 Aug 8.

PMID:
23869941
8.

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.

Am J Cardiol. 2012 Sep 15;110(6):845-51. doi: 10.1016/j.amjcard.2012.05.011. Epub 2012 May 30.

PMID:
22651881
9.

Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.

Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, Schein JR.

Curr Med Res Opin. 2014 Dec;30(12):2461-9. doi: 10.1185/03007995.2014.933577. Epub 2014 Jun 25.

PMID:
24926732
10.

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.

Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, Asukai Y, Saka Ö, Evers T, Faes P, Vansieleghem S, De Ruyck M.

Pharmacoeconomics. 2013 Oct;31(10):909-18. doi: 10.1007/s40273-013-0087-9.

11.
12.

A cost-analysis model for anticoagulant treatment in the hospital setting.

Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

J Med Econ. 2014 Jul;17(7):492-8. doi: 10.3111/13696998.2014.914032. Epub 2014 Apr 30.

PMID:
24773068
13.

Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view.

Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J.

J Med Econ. 2016 Aug;19(8):769-76. doi: 10.3111/13696998.2016.1171774. Epub 2016 Apr 24.

PMID:
27028360
14.

Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.

Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH.

J Med Econ. 2014 Nov;17(11):771-81. doi: 10.3111/13696998.2014.953682. Epub 2014 Aug 26.

PMID:
25133458
15.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
16.

Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.

Farr AM, Jing Y, Johnston S, Trocio J, Singhal S, Bruno A, Graham J.

Hosp Pract (1995). 2015;43(3):172-9. doi: 10.1080/21548331.2015.1071635. Epub 2015 Jul 27.

PMID:
26213178
17.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
18.

Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.

Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

J Med Econ. 2015;18(12):1041-9. doi: 10.3111/13696998.2015.1074583. Epub 2015 Aug 26.

PMID:
26201251
19.

Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.

Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y.

Cardiovasc Drugs Ther. 2014 Dec;28(6):575-85. doi: 10.1007/s10557-014-6558-1.

PMID:
25319314
20.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

Supplemental Content

Support Center